World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Research Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 845-861

ACADEMIC ANALYSIS OF DIVERSE RESEARCH IN PHARMACOLOGY

N. Satheeshkumar*, V. S. Bharathraj, R. Deepika, Dr. B. Sangameswaran and Dr. S. Kannan

Assistant Professor, Department of Pharmacology, SSM College of Pharmacy.

Article Received: 18 July 2025 | | ***Article Revised: 08 August 2025*** | | ***Article Accepted: 29 August 2025***

***Corresponding Author: N. Satheeshkumar**
Assistant Professor, Department of Pharmacology, SSM College of Pharmacy.
DOI: https://doi.org/10.5281/zenodo.17053897

How to cite this Article: N. Satheeshkumar, V. S. Bharathraj, R. Deepika, Dr. B. Sangameswaran and Dr. S. Kannan (2025) ACADEMIC ANALYSIS OF DIVERSE RESEARCH IN PHARMACOLOGY. World Journal of Pharmaceutical Science and Research, 4(4), 845-861. https://doi.org/10.5281/zenodo.17053897

INTRODUCTION

In drug development, preclinical development (also termed preclinical studies or nonclinical studies) is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug safety data are collected, typically in laboratory animals. The main goals of preclinical studies are to determine a starting, safe dose for first-in- human study and assess potential toxicity of the product, which typically include new medical devices, prescription drugs, and diagnostics. Companies use stylized statistics to illustrate the risks in preclinical research, such as that on average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug.

Types of Preclinical Research

Each class of product may undergo different types of preclinical research. For instance, drugs may undergo pharmacodynamics (what the drug does to the body) (PD), pharmacokinetics (what the body does to the drug) (PK), ADME, and toxicology testing. Medical devices that do not have drug attached will not undergo these additional tests and may go directly to good laboratory practices (GLP) testing for safety of the device and its components. Some medical devices will also undergo biocompatibility testing which helps to show whether a component of the device or all components are sustainable in a living model. Most preclinical studies must adhere to GLPs in ICH Guidelines to be acceptable for submission to regulatory agencies such as the Food & Drug Administration in the United States.

Typically, both *in vitro* and *in vivo* tests will be performed. Studies of drug toxicity include which organs are targeted by that drug, as well as if there are any long-term effects or toxic effects causing illness. *(*Annabey *et.al*, 2020)

Animal Testing

The information collected from these studies is vital so that safe human testing can begin. Typically, in drug development.

Studies animal testing involves two species. The most commonly used models are murine and canine, although primate and porcine are also used.

Fig. no. 1: Animal testing.

Choice of Species

1. Species selection is based on physiological similarity to humans to ensure accurate prediction of drug behaviour.
2. Key factors influencing model choice:

- Gastrointestinal anatomy
- Enzyme activity
- Circulatory system differences
- Drug dosage form and metabolism

3. Species-specific limitations:

- Canines: Not ideal for solid oral dosage forms due to fast gastric emptying and underdeveloped intestines.
- Rodents: Unsuitable for antibiotic studies due to disruption of intestinal flora causing severe side effects.
- Metabolic pathways may differ across species, affecting drug efficacy and toxicity.

4. Medical device testing:

- Conducted in larger animals (dogs, pigs, and sheep) for size and anatomical similarity to humans.
- Specific examples:
  - Swine: Skin and coronary studies
  - Goats: Mammary implant studies
  - Dogs: Gastric and cancer research

5. Regulatory Requirements:

- Agencies such as the FDA and EMA require safety testing in at least two mammalian species.
- One of these must be a non-rodent species before approval for human trial

Fig. no. 2: Choice of species.

Ethical Issues

Animal testing in the research-based pharmaceutical industry has been reduced in recent years both for ethical and cost reasons. However, most research will still involve animal based testing for the need of similarity in anatomy and physiology that is required for diverse product development.

Laboratory (Small) and Large Animal Models for Human Diseases

The importance of rat and mouse models has proved their outstanding importance in biomedical research. Besides, other mammalian and non-mammalian small domestic animals like the guinea pig, hamster, rabbit, ferrets, birds, amphibians, fishes, flies, worms have equal importance in terms of anatomical and physiological resemblance with humans. Large animal models also proved their uniqueness due to specific anatomical and physiological characteristics pertinent to those specific researches.

Transgenic Animal Models in Biomedical Research

Transgenic animal models have revolutionized biomedical research by allowing scientists to study human diseases in animals. These models involve introducing human genes into animal genomes, allowing researchers to study the effects of specific genetic mutations.

The CRISPR-Cas9 system has enabled precise gene editing in animals, making it possible to produce accurate human disease models. This technology has accelerated the development of new treatments and therapies.

Animal Models in Pharmaceutical Drug Development

1. Animal models are essential tools for pre-clinical drug screening prior to human clinical trials.
2. They provide critical in vivo data on:

- Drug efficacy
- Pharmacokinetics
- Safety
- Toxicological profiles (e.g., general toxicity, mutagenicity, carcinogenicity, teratogenicity)
- Potential for eye and skin irritation

3. Pre-clinical evaluation typically includes both in vitro and in vivo models to validate results.
4. Commonly used animals include mice, rats, and rabbits due to their biological similarities to humans and ease of laboratory handling.

5. Rodents are often preferred for early testing, but regulations now require simultaneous testing on non-rodent species (e.g., rabbits, dogs, cats, or primates). (Mukherjee, P., Roy, S., Ghosh, D. *et al*, 2022*)*

Animal Models in Medical Device Development

Definition of a Medical Device (According to the FDA)

A medical device is any instrument, apparatus, machine, implant, in vitro reagent, related article that is:

Recognized in the U.S. Pharmacopoeia or National Formulary. Intended for diagnosing, curing, treating, or preventing disease in humans or animals. Intended to affect the structure or function of the body without achieving its primary effect through chemical action or being metabolized. FDA Medical Device Classifications: Class I: Low risk, subject to general controls. Class II: Moderate risk, subject to general and special controls. Class III: High risk, subject to the most stringent regulatory controls (typically requires premarket approval).

Device Contact Categories

Surface-Contacting Devices: Contact skin, mucous membranes, or compromised surfaces. Examples: Skin tape, electrodes, contact lenses, orthodontic appliances. External Communicating Devices: Communicate with internal body systems like blood, tissue, or bone. Examples: IV administration sets, balloon catheters, dental cement, blood oxygenators. Implantable Devices: Implanted in the body and contact tissue, bone, or blood. Examples: Heart valves, vascular grafts, artificial joints, bone screws, breast implants.**(Pehlivanović Belma.et.al.2019.**

LITRATURE REVIEW

P. Mukherjee and S. Roy et.al July (2022) the animal model deals with the species other than the human, as it can imitate the disease progression, its' diagnosis as well as a treatment similar to human. Discovery of a drug and/or component, equipment, their toxicological studies, dose, side effects are in vivo studied for future use in humans considering its' ethical issues. Here lies the importance of the animal model for its enormous use in biomedical research. Animal models have many facets that mimic various disease conditions in humans like systemic autoimmune diseases, rheumatoid arthritis, epilepsy, Alzheimer's disease, cardiovascular diseases, Atherosclerosis, diabetes, etc., and many more. Besides, the model has tremendous importance in drug development, development of medical devices, tissue engineering, wound healing, and bone and cartilage regeneration studies, as a model in vascular surgeries as well as the model for vertebral disc regeneration surgery. Though, all the models have some advantages as well as challenges, but, present review has emphasized the importance of various small and large animal models in pharmaceutical drug development, transgenic animal models, models for medical device developments, studies for various human diseases, bone and cartilage regeneration model, diabetic and burn wound model as well as surgical models like vascular surgeries and surgeries for intervertebral disc degeneration considering all the ethical issues of that specific animal model. Despite, the process of using the animal model has facilitated researchers to carry out the researches that would have been impossible to accomplish in human considering the ethical prohibitions.

William W Stoops et.al March (2022) Human behavioral pharmacology methods have been used to rigorously evaluate the effects of a range of centrally acting drugs in humans under controlled conditions for decades. Methods like drug self-administration and drug discrimination have been adapted from nonhuman laboratory animal models. Because humans have the capacity to communicate verbally, self-report methods are also commonly used to understand drug effects. This perspective article provides an overview of these traditional human behavioral pharmacology

methods and introduces some novel methodologies that have more recently been adapted for use in the field. Design (e.g., using placebo controls, testing multiple doses) and ethical (e.g., avoiding enrollment of individuals seeking treatment, determining capacity to consent) considerations that must be addressed when conducting these types of studies are also described.

Francesca Stanzione May (2021) Molecular docking has become an important component of the drug discovery process. Since first being developed in the 1980s, advancements in the power of computer hardware and the increasing number of and ease of access to small molecule and protein structures have contributed to the development of improved methods, making docking more popular in both industrial and academic settings. Over the years, the modalities by which docking is used to assist the different tasks of drug discovery have changed. Although initially developed and used as a standalone method, docking is now mostly employed in combination with other computational approaches within integrated workflows. Despite its invaluable contribution to the drug discovery process, molecular docking is still far from perfect. In this chapter we will provide an introduction to molecular docking and to the different docking procedures with a focus on several considerations and protocols, including protonation states, active site waters and consensus,that can greatly improve the docking results.

Pehlivanović Belma june (2019) Animal models represent unique source of in vivo data for various fields of biomedical research. In today's pharmaceutical drug development, animal models are used as pre-clinical tools for potential drug screening process and translation into clinical trials. These models are most commonly used as in vivo models for evaluation of basic pharmacokinetic parameters, drug efficiency and safety. Selection of ideal animal model for biomedical research is crucial part of research process as there are important parameters that researcher have to have in mind when selecting animals for their trials. In field of tissue engineering very important contribution is given by usage of various animal models. For in vivo testing of medical devices a variety of animal species can be used to define a model. This is important in gathering preliminary information on the safety and, in some cases, effectiveness of a device. This review describes application of animal models in different fields of biomedical research, such as drug and medical devices development, and hopes to summarize main properties needed for selection of ideal animal model in biomedical researc

AIM AND OBJECTIVES

Aim

The overarching goal is to provide a detailed overview of research methodologies relevant to pharmacology, including experimental, observational, and qualitative studies.

Objectives

- Understanding Research Paradigms
- Mastering Quantitative and Qualitative
- Data Analysis Techniques
- Ethical Considerations
- Research Design and Planning

PLAN OF WORK

OVERVIEW OF

- ***in vitro*** method
- ***in vivo*** method
- ***ex vivo*** method
- ***in silicon*** method



Fig. no. 3: plan of work.

TECHNIQUES

In vitro **methods**

- ✓ Cell culture studies
- ✓ Receptor binding Assay
- ✓ Enzyme Assay
- ✓ Antioxidant assay

CELL CULTURE STUDIES

Cell culture involves the cultivation of nucleated (eukaryotic) cells under controlled laboratory conditions. It is essential for isolating infectious agents that require living host cells for replication. Although molecular diagnostic assays based on nucleic acid detection have reduced the routine use of cell culture in clinical diagnostics—due to their faster turnaround times, lower costs, and less reliance on technical expertise—cell culture remains a critical tool in several key areas. These include the discovery of new pathogens, the identification of disease-causing organisms when molecular or serological tests are inconclusive or unavailable, the propagation of isolates for research, the development of vaccines, and the evaluation of novel antimicrobial therapies.

In veterinary medicine, vaccines for diseases such as canine distemper, canine adenovirus, parvovirus, rabies, and feline viral and chlamydial respiratory tract infections are commonly produced using cell culture. Therefore, veterinary clinicians must understand when cell culture is the most appropriate diagnostic method and be familiar with proper specimen collection and submission protocols. A solid understanding of cell culture techniques also enables clinicians

to better interpret laboratory results, appreciate turnaround times, and anticipate potential challenges in diagnosis and treatment.



Fig. no. 4: cell culture.

Specimen Collection and Transport

Although cell culture can be used to propagate intracellular bacteria and protozoa, it is most commonly used for the diagnosis of viral infections. Effective communication between the veterinary clinician and the diagnostic laboratory is essential for successful viral isolation. Accurate virus detection relies on three critical factors:

1. Collecting the appropriate type of specimen,
2. Timing the collection properly,
3. Ensuring rapid and proper transport and processing of the sample.
4. The clinician plays a vital role in achieving diagnostic success. It is important to inform the laboratory about the suspected viruses based on clinical presentation, as different viruses have preferences for specific host cell types. This information helps guide appropriate cell culture selection and processing techniques.

Timing is crucial: Specimens should ideally be collected early in the course of disease— preferably within the first week after the onset of clinical signs—because viral shedding often begins before signs appear and may last only a few days. The duration of shedding depends on the virus and the anatomical site sampled.

When multiple animals are affected, submitting samples from several individuals increases the likelihood of isolating the pathogen. In addition, acute and convalescent serology should be performed concurrently when possible, to aid in confirming the diagnosis.

Maintenance of Cell Cultures in the Laboratory

In the lab, cells are generally grown as a monolayer on plastic culture plates. These monolayer cells can be:

- Primary cell cultures: Derived directly from animal tissues. These closely resemble in vivo cells but have a limited lifespan. They are essential for isolating certain viruses that do not grow well in immortalized lines.
- Continuous cell lines: Immortalized cells that can be maintained indefinitely but may be less sensitive to some viral infections.

Primary cultures are especially important for isolating viruses that replicate more efficiently in natural, less-modified cell types. However, repeated sub culturing of these cells reduces their susceptibility to viral infection.

Primary cultures are established by:

- Treating tissue samples with enzymes like trypsin or collagenase, followed by incubation in culture media.
- For white blood cells (e.g., peripheral blood mononuclear cells), density gradient centrifugation is used to separate them from other blood components before culturing.



Fig. no. 5: Procedure cell culture.

Inoculation of Cell Cultures

1. Inoculation Process

Growth medium is removed from the monolayer. A suspension containing viral or bacterial organisms is added. Tissue specimens must be homogenized in culture medium before use. Samples may be centrifuged or filtered to remove debris and bacteria. Inoculum remains on the monolayer for ~1 hour, then removed .Fresh maintenance medium is added after inoculation.

2. Detection of Viral Infection

Monolayers are examined daily for cytopathic effects (CPE). Medium is replaced weekly or biweekly. CPE includes cell lysis, rounding, detachment, or syncytium (cell fusion). CPE is compared to control cultures to confirm infection. Example: Feline calicivirus (FCV) shows CPE within 16–24 hours.

3. Additional Diagnostic Tools

Light microscopy: used to observe inclusion bodies and syncytia. Hem adsorption: used for viruses that do not produce visible CPE. Fluorescent antibody staining: detects virus- specific proteins. PCR or RT-PCR: detects viral nucleic acids. Electron microscopy: confirms viral presence and morphology

For example

file:///C:/Users/DELL/Downloads/Cell%20Culture,%20Technology_%20Enhancing%20the%20Culture%20of%20Diagnosing%20Human%20Diseases%20-%20PMC.htm

https://youtu.be/nr1tV_LuqJk?si=U8om_wKthGJ-5iQG

***In vivo* Methods**

- ✓ Animal model for disease
- ✓ Behavioural studies in rodents
- ✓ Toxicity and safety evaluation
- ✓ Pharmacokinetic/pharmacodynamics studies

Toxicity and safety evaluation

Preclinical toxicology is a vital phase in drug development, focusing on assessing the safety of new drug candidates before clinical trials. This research aims to identify potential toxic effects, determine safe dosage levels, and predict human safety outcomes.



Fig no 6: Toxicity studies Key Components of Preclinical

Toxicology

1. **Acute Toxicity Testing**: Evaluates the effects of a single dose over a short period.
2. **Chronic/Sub-chronic Toxicity Testing**: Assesses the impact of repeated doses over extended periods.
3. **Genetic Toxicity**: Investigates potential DNA damage or mutations
4. **Reproductive Toxicity**: Examines effects on fertility and offspring development.
5. **Carcinogenicity**: Determines the potential for cancer development.

Creative Bio array's Preclinical Toxicology Services

Creative Bio array offers comprehensive preclinical toxicology services, including:

Administration Routes: Oral, intraperitoneal, intravenous, topical, intramuscular, and more.

- **Animal Models**: Mice, rats, rabbits, mini pigs, guinea pigs, dogs, and non-human primates.
- **Toxicology Assessments**: Acute and chronic toxicity, genetic toxicity, reproductive toxicity, and carcinogenicity.
- **Comprehensive Analyses**: Chemistry, histopathology, hematology, urinalysis, ophthalmology, bioanalysis, and toxic kinetics.

These services are designed to support the safe development of new drugs and facilitate regulatory submissions.
For more information, visit Creative Bio array's In Vivo Toxicity Study page.

Tests for the *in Vivo* Toxicology

- Dose-range finding assay
- Acute systemic repeat-dose toxicity assay (3 to 7 days)
- Maximum tolerated dose (MTD)
- Median lethal dose (LD50)
- Toxic dose (TD)
- Minimal toxic dose (MTD)
- Median effective dose (ED50)
- Therapeutic index (TI)
- NOAEL
- Subacute repeat-dose toxicity assay (14 to 30 days)
- Sub-chronic repeat-dose toxicity assay (longer than 30 days)
- Investigational new drug (IND) enabling studies assay
- Dose escalation studies assay
- Toxic kinetics (TK)

1. Dose-Range Finding Assay

Determines the maximum safe dose of a drug by administering varying doses to animals. This helps establish the therapeutic index and identify the highest dose that does not cause unacceptable side effects.

2. Single and Repeat-Dose Toxicity Assay

- **Single-Dose Studies**: Evaluate the immediate toxic effects of a single drug dose.
- **Repeat-Dose Studies**: Assess the effects of multiple doses over time, identifying potential cumulative toxicities.

3. Acute, Sub-Chronic, and Chronic Toxicity Assays

- **Acute Toxicity**: Examines the effects of a single, high dose over a short period.
- **Sub-Chronic Toxicity**: Studies the impact of repeated doses over a medium duration.
- **Chronic Toxicity**: Assesses long-term exposure effects, including behavioral and reproductive change.

4. Safety Pharmacology

Investigates how a drug affects vital systems like the nervous, cardiovascular, and respiratory systems to predict potential life-threatening effects.

5. Local Tolerance Assay

Evaluates irritation or adverse reactions at the site of drug administration, ensuring the formulation is safe for intended delivery routes.

6. Geno toxicity Assay

Detects potential DNA damage caused by a drug, which could lead to cancer or genetic mutations.

7. Carcinogenicity Assay

Long-term studies to determine if a drug has the potential to cause cancer after prolonged exposure.

8. Reproductive Toxicity Assay

Assesses the impact of a drug on fertility, embryo development, and offspring health across generations.

9. Immune toxicity Assay

Evaluates how a drug affects the immune system, including potential allergic reactions or suppression of immune responses.



Fig. no. 7: Types of toxicity.

Available Administration Routes

- Dermal
- Oral gavage
- Intranasal
- Intra tracheal
- Dietary
- Subcutaneous
- Intraperitoneal
- Intravenous
- Intramuscular



Fig. no. 8: Types of route of administration.

Species

- Mice
- Rats
- Rabbits
- Guinea Pigs
- Non-human Primates
- Zebra fish

Toxicity Endpoints

- **States of Animal Living**: Monitoring mortality, body weights, clinical observation, and appetite.
- **Clinical Pathology**: Assessing hematology, serum chemistry, urinalysis, coagulation factors, and pathological findings.
- **Toxic kinetic Parameters**: Studying the absorption, distribution, metabolism, and excretion of compounds.

Study Design

- Flexible protocols tailored to meet specific scientific project needs.
- Expertise in dosing, clinical observation, and sample collection.
- Support from clinical laboratories, and pathologists.

For example

https://www.mdpi.com/1420-3049/20/12/19839

https://youtu.be/7y0dzswgyHM?si=38weavkh5cpp2Mpp

***Ex vivo* method**

- ✓ Organ bath
- ✓ Tissue perfusion studies

ORGAN BATH

An **organ chamber**, **organ bath**, or **isolated tissue bath**, is a chamber in which isolated organs or tissues can be administered with drugs, or stimulated electrically, in order to measure their function. The tissue in the organ bath is typically oxygenated with carbon and kept in a solution such as Tyrone's solution or lactated Ringer's solution. Historically, they have also been called **gut baths**.

Overview

Organ Bath Techniques in Pharmacology Research

Organ bath systems are pivotal in pharmacology for studying smooth muscle contraction in tissues such as the ileum, colon, vas deferens, trachea, bladder, corpus cavernous, and blood vessels like aortic rings. These systems allow for the measurement of physiological responses, providing insights into drug effects on various tissues.

Applications

- **Tissue Types Studied**: Commonly used tissues include those from rodents like guinea pigs, mice, and rats.
- **Receptor Studies**: Organ baths facilitate the study of various receptors, including nicotinic, muscarinic, histamine, and beta-adrenoceptors, by observing tissue responses to specific agonists and antagonists.
- **Drug Profiling**: These systems enable the generation of dose-response curves, allowing for the calculation of pharmacological parameters such as EC50 (effective concentration for 50% of maximal response), IC50 (half-maximal inhibitory concentration), and the Hill coefficient.

Advantages

- **Whole-Tissue Functionality**: Unlike isolated cells, organ baths maintain the tissue's natural architecture and function, providing more physiologically relevant data.
- **Real-Time Analysis**: Researchers can observe and adjust experiments in real-time, enhancing the flexibility and responsiveness of the study.
- **Reproducibility**: The method's simplicity and consistency make it a reliable tool for pharmacological research.

Modern Alternatives

While organ bath techniques have been foundational, newer methods like high- throughput screening, pharmacogenomics, and proteomics offer more receptor-specific Insights. These advanced techniques can analyses multiple receptor types simultaneously, providing a broader understanding of drug interactions.

Fig. no. 9: Organ Bath.

For example

https://pmc.ncbi.nlm.nih.gov/articles/PMC7220716/

https://youtu.be/Weipo6y_asw?si=uKRe9chm44xfhYR1

***In silco* method**

- ✓ Molecular docking.
- ✓ Quantitative structure-activity relationship (QSAR)
- ✓ Pharmacophore modelling
- ✓ ADMET prediction

MOLECULAR DOCKING

Molecular docking is a computational technique used to predict the optimal binding mode of a ligand (a small molecule) to a receptor (typically a protein), aiming to achieve the most favorable interaction based on geometric and energetic complementarity. This process helps in estimating the binding affinity and understanding the interaction mechanisms between the two molecules.



Fig. no. 10: Molecular Docking.

The "lock-and-key" model, first proposed by Emil Fischer in 1894, illustrates this concept by likening the enzyme (receptor) to a lock and the substrate (ligand) to a key. In this analogy, only a key with a complementary shape can fit into the lock, emphasizing the importance of geometric specificity in molecular interactions. This model assumes that both the ligand and receptor have rigid, pre-formed structures that fit together perfectly without any conformational changes upon binding. However, this model has limitations, particularly in explaining interactions where conformational changes occur upon binding. To address this, the "induced fit" model was introduced, suggesting that the binding of a ligand can induce a conformational change in the receptor, enhancing the fit and specificity of the interaction. This model accounts for the dynamic nature of molecular interactions, where both the ligand and receptor may undergo structural adjustments to achieve optimal conformation and orientation.

Types of Molecular Docking

Docking methods are categorized based on the flexibility of the ligand and receptor:

- **Rigid Docking**: Assumes both the ligand and receptor are inflexible. This approach is computationally efficient but may overlook conformational changes upon binding.

- **Flexible Docking**: Allows flexibility in the ligand and/or receptor, providing a more accurate representation of molecular interactions.
- **Flexible-Rigid Docking**: Involves a flexible ligand docking to a rigid receptor, balancing computational efficiency and accuracy.dock.compbio.ucsf.edu Flexible-rigid docking has gained prominence due to its balance between computational efficiency and the ability to model conformational changes upon binding.

Widely Used Molecular Docking Software

Several software packages are commonly utilized in molecular docking studies

- **Auto Dock and Auto Dock Vine**: Open-source tools developed by Scripps Research, widely used for protein-ligand docking. Auto Dock Vina offers improved speed and accuracy compared to its predecessor. Wikipedia
- **Glide**: A proprietary software developed by Schrödinger, Inc., known for its high accuracy in predicting binding modes and affinities. Wikipedia
- **R Dock**: An open-source molecular docking software developed by Vernalis R&D, suitable for docking small molecules against proteins and nucleic acids, with a focus on high-throughput virtual screening. Wikipedia
- **R DKit**: An open-source cheminformatics toolkit that provides functionalities for molecular docking, among other applications.

Molecular Docking Databases

Several databases provide essential resources for molecular docking studies:

- **Protein Data Bank (PDB)**: A comprehensive repository of 3D structural data of large biological molecules, crucial for understanding molecular interactions.
- **PubChem**: A free resource for chemical molecules and their biological activities, maintained by the National Centre for Biotechnology Information (NCBI). Wikipedia
- **ZINC**: A free database of commercially available compounds for virtual screening.
- **Cambridge Structural Database (CSD)**: A repository of small-molecule organic and metal-organic crystal structures, valuable for understanding molecular interactions.

For example

https://www.sciencedirect.com/science/article/pii/S0010482522002463

https://youtu.be/u49k72rUdyc?si=FgnIYTf8PxRlsXvc

SUMMARY & DISCUSSION

Pharmacology Research employs a diverse range of methodologies including experimental, observational, and clinical trial designs. These methods helps researchers understand drug mechanism, efficacy, safety and optimal use.

CONCLUSION

Pharmacology research relies on a diverse range of methodologies to comprehensively study drug action and to impact on living systems. The field is constantly evolving. Incorporation new technologies and approaches to advance drug delivery and improve patient care.

Furthermore, the increasing emphasis on diversity and inclusion in Pharmacological research ensures that findings are relevant and beneficial to all populations.

ACKNOWLEDGEMENT

With the blessings of the Lt. Mr. K. S. Elavarashen, B. Com **Chairman, SSM College of Pharmacy, JAMBAI.**

My special thanks to **Mr.K.P.E.Ravindran, M.B.A.,** Correspondent, SSM College of Pharmacy, Jambai for providing infrastructure and facilities required for this research work.

We would like to thank our **Vyarathi Charitable and Educational trust** Members for providing the necessary facilities.

It is a privilege to extend my gratitude to **Prof.Dr.B.Sangameswaran., M.Pharm., Ph.D.,** Principal, SSM College of Pharmacy, Jambai. for his valuable suggestion, encouragement, guidance and constant support to carry out my project work.

It is immense pleasure to thank my guide **Mr. N. SatheeshKumar., M.Pharm.,** Department of Pharmacology for his excellence in guidance, contribution and encouragement which helped us in the successful completion of each and every stage of my project work.

We express our special thanks to all the faculties from the Department of pharmacology **Dr. S. Kannan, M.Pharm., Ph.D, Mr. N. Satheeshkumr., M.Pharm, Mr. L. K. Sridharan., M.Pharm, Mrs. M. Latha., M.Pharm, Mrs.P.Hemadharshni., M.Pharm, Mr.T.Ganeshkumar.,M.Pharm, Mr.S.Arun.,.M.Pharm, Mr. N. Murugan., M.Pharm, Mr. R. Bharath., B.Pharm.**

We would like to thank my seniors and juniors for their moral support to carry out this project work.

We would like to thank our library madam for her moral support.

We would like to express to our heartfelt thanks to my parents, brothers and sisters for their moral support to successful carryout my Practice school work.

ABBREVIATIONS	EXPANSION
PK	PharmacoKinetics
PD	PharmacoDynamic
GLP	Good Laboratory Practice
ICH	International Council for Harmonisation
FDA	Food and Drug Administration
EMA	European Medicines Agency
CRISPR-Cas9	Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9
CPE	Cytopathic Effect
RT- PCR	Reverse Transcription Polymerase Chain Reaction
FCV	Fuseline Calici virus
DNA	Deoxyribo Nucleic Acid
MTD	Minimal Toxic Dose
ED50	Median Effective Dose
IND	Investigational New Drug
NOAEL	No Observed Adverse Effect Level
TK	Toxicity Kinetics

EC50	Effective Concentration for 50% of Maximal response
IC50	Half-Maximal Inhibitory Concentration
QSAR	Quantitative Structure-activity Relationship
ADMET	Absorption, Distribution, metabolism, Excretion and Toxicity
PDA	Protein Data Bank
CSD	Cambridge Structural Database
NCBI	National Centre for Biotechnology Information

REFERENCES

1. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM, Schuster D, Breuss JM, Bochkov V, Mihovilovic MD, Kopp B, Bauer R, Dirsch VM, Stuppner H *"Discovery and resupply of pharmacologically active plant- derived natural products: A review"*. Biotechnology Advances, December 2015; 33(8): *1582*–1614. *doi*:*10.1016/j.biotechadv.2015.08.001*.*PMC 4748402*. *PMID 262817202*
2. Berman, H., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T., Weissig, H., Shindyalov, and Bourne, P. the Protein Data Bank, 1999 —. In: International Tables for Crystallography, Eds. Rossmann, M. G. and Arnold, E., 2000; 67: 675–684.
3. Chen, Y. Z. and Zhi, D. G. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins, 2001; 43: 217–226
4. Dusinska, M.; *et al*. Chapter 3 - Toxicity Tests: In Vitro and In Vivo. In B. Fadeel, Pietroiusti, & A. A. Shvedova (Eds.), *Adverse Effects of Engineered Nanomaterials (Second Edition)* (pp. 51–82). Academic Press. (2017).
5. "Drug Approvals - From Invention to Market...12 Years!". *MedicineNet*. Retrieved 2021-04-21.
6. Emanuel EJ (9 September 2015). "The Solution to Drug Prices". New York Times. On average, only one in every 5,000 compounds that drug companies discover and put through preclinical testing becomes an approved drug. Of the drugs started in clinical trials on humans, only 10 percent secure F.D.A. approval.
7. Fielden, M. R.; Kolaja, K. L. The role of early in vivo toxicity testing in drug discovery toxicology. *Expert Opinion on Drug Safety*, 2008; *7*(2): 107-110
8. Heikkinen T, Marttila J, Salmi AA,et,al. nasal swab versus nasopharyngeal aspirate for isolation of respiratory viruses. ClinMicrobiol, 2002; 40(11): 4337- 4339.
9. Moran CJ, Ramesh A, Brama PAJ, O'Byrne JM, O'Brien FJ, Levingstone TJ. The benefits and limitations of animal models for translational research in cartilage repair. J Exp Orthop. 2016; 3(1):1.
10. Morris, G. M. and Lim-Wilby, M. Molecular docking. Methods Mol. Biol., 2008; 443: 365–382.
11. Pehlivanovic B, Dina F, Emina A, Ziga Smajic N, Fahir B. Animal models in modern biomedical research. Eur J Pharm Med Res, 2019; 6(7): 35–8.
12. Simmons D. The use of animal models in studying genetic disease: transgenesis and induced mutation. Nat Educ, 2008; 1(1): 70.
13. file:///C:/Users/DELL/Downloads/Preclinical%20development%20-%20Wikipedia.htm
14. file:///C:/Users/DELL/Downloads/Role%20of%20animal%20models%20in%20biomedical%20research_%20a%20review%20_%20Laboratory%20Animal%20Research. htm
15. file:///C:/Users/DELL/Downloads/Research%20Methods%20in%20Pharmacol.ht m
16. file:///C:/Users/DELL/Downloads/In%20Vivo%20Toxicity%20Study%20_%20C reative%20Bioarray.htm
17. file:///C:/Users/DELL/Downloads/Progress%20in%20molecular%20docking%20_%20Quantitative % 20Biology.htm